

AMENDMENTS TO THE FIGURES

Please replace Figures 2a, 2b, 2c, and 2d with the Replacement Sheets for each of these figures that are submitted herewith.

Please delete Figure 2e.

Please delete Figure 4a.

REMARKS

Applicants have studied the Office Action mailed September 12, 2005 and have made amendments to the specification and figures. It is respectfully submitted that the application, as amended, is in condition for allowance. Reconsideration and allowance of the application in view of the above amendments and the following remarks is respectfully requested.

Sequence Compliance:

The Examiner stated that the application fails to comply with the requirements of 37 CFR 1.821 through 1.825 because there are numerous sequence disclosures in both the specification, and particularly in the drawings, where applicants have failed to a) provide a SEQ ID NO for the sequence, or b) failed to properly indicate what part of SEQ ID NO:1 the primer, SNP, oligo, etc.

Applicants have hereby deleted Table 3 and Table 4 from the specification, amended Figures 2a, 2b, 2c, and 2d by way of Replacement Sheets submitted herewith, and deleted Figures 2e and 4a. Figures 2a, 2b, 2c, and 2d have been amended to remove material that is not specifically claimed in the instant claims, and to insert sequence identifiers where relevant (SEQ ID NOS:3-12).

Furthermore, a Substitute Sequence Listing is submitted herewith that includes SEQ ID NOS:3-12 from Figures 2a, 2b, 2c, and 2d.

Conclusions

The above amendments to the specification and figures have been made in order to bring the application into compliance with the sequence requirements.

In the September 12, 2005 Office Action, the Examiner stated that claims 18-19, 24-26, 28-29, and 32-33 are pending. However, in the Notice of Allowability mailed June 24, 2005, the Examiner indicated that claim 27 was also pending (and allowed). Applicants respectfully request clarification of the status of claim 27.

In view of the above remarks and amendments, Applicants respectfully submit that the application is in condition for allowance. If for any reason the Examiner finds the application other than in condition for allowance, the Examiner is invited to call the undersigned agent at (240) 453-3812 should the Examiner believe a telephone interview would advance prosecution of the application.

Respectfully submitted,
CELERA GENOMICS

Date: November 14, 2005

By: 

Justin D. Karjala, Reg No. 43,704

Celera Genomics Corporation
45 West Gude Drive
Rockville, MD 20850
Tel: 240-453-3812
Fax: 240-453-3084

Attachment:

- Replacement Sheets of drawings for Figures 2a, 2b, 2c, and 2d.